ClinicalTrials.gg
CompletedNCT03210623Updated Sep 12, 2018

Stent Retriever's(TonbridgeMT) Endovascular Therapy for Acute Ischemic Stroke(AIS)

An interventional study of stent retriever(TonbridgeMT) and Solitaire™ in Ischemic Stroke, sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd.. Completed at 17 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-12.

Sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Enrollment
322nd of 566
220 · median 271
Started
2017
with 17 others
No phase
247 of 754
122 open now
Registered
88th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 322nd largest by enrollment of the 566 interventional ones that give a count, is one of 18 that started in 2017, is one of 247 with no phase, and was the 88th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

The study is a prospective, multi-center, stratified randomized, single-blind, parallel assignment, active control, non-inferiority trial. Patients are randomized 1 : 1 to either stent retriever(TonbridgeMT) or Solitaire™ for endovascular therapy for AIS. The study aims to evaluate the benefit and safety of stent retriever(TonbridgeMT) for AIS therapy, as compared to Solitaire™.

Read the detailed description

The main objective is to determine whether stent retriever(TonbridgeMT) will have non-inferior successful recanalization rate compared to Solitaire™ when applied to endovascular therapy for AIS.

The secondary objectives is to verify whether there isn't significant differences in time to achieve recanalization, NIHSS score, mRS score, and transportation performance between stent retriever(TonbridgeMT) and Solitaire™ when applied to endovascular therapy for AIS.

The third objectives is to verify whether there isn't significant differences in the rate of symptomatic intracranial hemorrhage, subarachnoid hemorrhage, adverse event(AE), serious adverse event(SAE), actual condition of AE and device deficiencies between stent retriever(TonbridgeMT) and Solitaire™ when applied to endovascular therapy for AIS.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18≤ages≤80;
  2. Baseline NIHSS score obtained prior to randomization must be lower than 30 points;
  3. Acute occlusion(TICI 0-1) of the intracranial segment of internal carotid artery(ICA), or M1/M2 middle cerebral artery(MCA), or A1/A2 anterior cerebral artery(ACA), as evidenced by digital subtraction angiography(DSA);
  4. Patient treatable within 6 hours of symptom onset(symptoms onset is defined as point in time the patient was last seen well (at baseline)) can accept the complete femoral artery puncture;
  5. Pre-AIS mRS score lower than 2.

Exclusion criteria

Exclusion Criteria:

  1. Computed tomography (CT) or magnetic resonance imaging (MRI) evidence of intracranial hemorrhage or massive cerebral infarction (ASPECTS score of\<6 or infarct volume≥70ml or volume>1/3 blood supplying areas of MCA on CT/diffusion weighted imaging(DWI);
  2. DSA evidence of simultaneous acute bilateral carotid occlusion;
  3. DSA evidence of occlusions in the initial segment of carotid artery or carotid artery dissection or arteritis;
  4. DSA evidence of tortuosity of cervical vessels precluding device delivery/deployment;
  5. Hypertension (Systolic blood pressure(SBP)>185 mm Hg or diastolic blood pressure(DBP)>110 mm Hg) after using drug;
  6. count\<40,000/μL and use of Novel Anticoagulant with (INR)>3.0;
  7. Random blood glucose of\<2.7mmol/L or>22.2mmol/L;
  8. Patients with heart or lung or liver or renal failure or other sever disease(intracranial tumors, cerebral arteriovenous malformation (AVM), systemic infection, active disseminated intravascular coagulation, myocardial infarction within the past 12 months before enrollment, history of sever psychosis);
  9. Patients who will not cooperate or tolerate interventional operation;
  10. Anticipated of less than 90 days;
  11. Allergy to contrast medium;
  12. Females who are pregnant or breastfeeding;
  13. Participation in any other clinical trial within the past 1 months before screening and follow-up;
  14. The patient or the patient's legally authorized representative hasn't signed and dated an form;
  15. Other factors that would cause harm or increased risk to the participant or close contacts, or preclude the participant's full adherence as per investigator's judgement.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    group A

    subjects applying the stent retriever(TonbridgeMT)

    Device: stent retriever(TonbridgeMT)

  • Active comparator
    group B

    subjects applying Solitaire™

    Device: Solitaire™

Interventions

  • Devicestent retriever(TonbridgeMT)

    mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)

  • DeviceSolitaire™

    mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)

06

What researchers measure

Primary outcomes

  1. successful recanalization rate in patients

    Successful recanalization is defined as modified Thrombolysis In Cerebral Ischemia scale 2b or 3. And it is evaluated by DSA intraoperative immediately in both treatment groups

    Time frame: intraoperative immediate

Secondary outcomes

  1. successful recanalization rate in vessels

    The proportion of successful recanalized vessels in all targeted vessels which receive the stent retriever treatment

    Time frame: intraoperative immediate

  2. Time to achieve recanalization

    The period from femoral artery puncture to successful recanalization

    Time frame: intraoperative immediate

  3. NIHSS score

    National Institutes of Health Stroke Scale

    Time frame: baseline, 24±6d and 7±2d after operation

  4. mRS score

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.

    Time frame: baseline, 90±14d after operation

  5. the ratio of mRS 0-2

    The proportion of patients who got a mRS 0-2 in patients who receive stent retriever treatment

    Time frame: baseline, 90±14d after operation

  6. transportation performance

    The proportion of stent retriever which can push and draw back well during the operation. The operator will grade each stent retriever at four level, namely great, good, average,and bad

    Time frame: intraoperative immediate

07

Study locations

17 sites
  • Changhai Hospital of Shanghai
    Shanghai, Shanghai, China
  • The 306th Hospital of Chinese PLA
    Beijing, China
  • China-Japan union hospital
    Changchun, China
  • The First Hospital of Jilin University
    Changchun, China
  • The First People's Hospital of Changzhou
    Changzhou, China
  • The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
    Guangzhou, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, China
  • Hangzhou First People's Hospital
    Hangzhou, China
  • The Second Affiliated hospital of Zhejiang University School of Medicine
    Hanzhou, China
  • Nanjing First Hospital Affiliated to Nanjing Medicine University
    Nanjing, China
  • Nanning People's Hospital
    Nanning, China
  • The Third People's Hospital of Hubei Province
    Wuhan, China
  • Tangdu Hospital
    Xi'an, China
  • Henan Provincial People's Hospital
    Zhengzhou, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
  • Zhongshan People's Hospital
    Zhongshan, China
  • The Fifth Affiliated Hospital Sun Yat-sen University
    Zhuhai, China
08

References and documents

Publications

  • Zhang Y, Hua W, Li Z, Peng Y, Han Z, Li T, Yin C, Wang S, Nan G, Zhao Z, Yang H, Zhou B, Li T, Cai Y, Zhang J, Li G, Peng X, Guan S, Zhou J, Ye M, Wang L, Zhang L, Hong B, Zhang Y, Wan J, Wang Y, Zhu Q, Liu J, Yang P. Efficacy and Safety of a Novel Thrombectomy Device in Patients With Acute Ischemic Stroke: A Randomized Controlled Trial. Front Neurol. 2021 Aug 12;12:686253. doi: 10.3389/fneur.2021.686253. eCollection 2021. PubMed 34456847 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Aug 2018, 12 months.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 12 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2017
First posted
Jul 7, 2017
StartActual
Aug 3, 2017
Primary completionActual
Aug 27, 2018
CompletionActual
Aug 27, 2018
Last update
Sep 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03210623
Lead sponsor
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Collaborators
Guangzhou Osmunda Medical Device Technology, Inc., Ltd.
Responsible party
Sponsor
First posted
Jul 7, 2017
Start date
Aug 3, 2017
Primary completion
Aug 27, 2018
Completion
Aug 27, 2018
Last update
Sep 12, 2018

Study contacts

Jianmin Liu
principal investigator · Changhai Hospital of Shangha

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion